This company listing is no longer active
CTI BioPharma Past Earnings Performance
Past criteria checks 0/6
CTI BioPharma's earnings have been declining at an average annual rate of -26.7%, while the Biotechs industry saw earnings growing at 10.8% annually. Revenues have been growing at an average rate of 20.1% per year.
Key information
-26.7%
Earnings growth rate
-8.2%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | 20.1% |
Return on equity | n/a |
Net Margin | -91.4% |
Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How CTI BioPharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 23 | 76 | -69 | 89 | 39 |
31 Dec 22 | 54 | -93 | 85 | 37 |
30 Sep 22 | 33 | -112 | 86 | 36 |
30 Jun 22 | 15 | -121 | 78 | 37 |
31 Mar 22 | 2 | -118 | 67 | 38 |
31 Dec 21 | 0 | -98 | 56 | 39 |
30 Sep 21 | 0 | -76 | 37 | 38 |
30 Jun 21 | 0 | -63 | 27 | 35 |
31 Mar 21 | 0 | -58 | 21 | 32 |
31 Dec 20 | 0 | -52 | 18 | 26 |
30 Sep 20 | 0 | -46 | 17 | 21 |
30 Jun 20 | 2 | -44 | 17 | 22 |
31 Mar 20 | 3 | -41 | 18 | 22 |
31 Dec 19 | 3 | -40 | 19 | 24 |
30 Sep 19 | 17 | -31 | 20 | 27 |
30 Jun 19 | 16 | -36 | 21 | 29 |
31 Mar 19 | 16 | -36 | 22 | 32 |
31 Dec 18 | 26 | -29 | 22 | 36 |
30 Sep 18 | 13 | -45 | 24 | 36 |
30 Jun 18 | 14 | -42 | 24 | 34 |
31 Mar 18 | 35 | -29 | 26 | 33 |
31 Dec 17 | 25 | -45 | 31 | 33 |
30 Sep 17 | 34 | -37 | 36 | 33 |
30 Jun 17 | 37 | -54 | 45 | 44 |
31 Mar 17 | 22 | -75 | 47 | 51 |
31 Dec 16 | 57 | -52 | 47 | 63 |
30 Sep 16 | 60 | -74 | 53 | 75 |
30 Jun 16 | 56 | -78 | 52 | 75 |
31 Mar 16 | 50 | -91 | 55 | 78 |
31 Dec 15 | 16 | -123 | 56 | 75 |
30 Sep 15 | 23 | -138 | 54 | 75 |
30 Jun 15 | 61 | -101 | 53 | 73 |
31 Mar 15 | 61 | -96 | 54 | 68 |
31 Dec 14 | 60 | -96 | 58 | 63 |
30 Sep 14 | 75 | -42 | 58 | 51 |
30 Jun 14 | 36 | -69 | 54 | 41 |
31 Mar 14 | 35 | -59 | 50 | 35 |
31 Dec 13 | 35 | -50 | 44 | 32 |
30 Sep 13 | 2 | -79 | 39 | 33 |
30 Jun 13 | 1 | -77 | 38 | 32 |
31 Mar 13 | 1 | -117 | 39 | 33 |
31 Dec 12 | 0 | -115 | 41 | 31 |
30 Sep 12 | 0 | -114 | 42 | 37 |
Quality Earnings: CEPS is currently unprofitable.
Growing Profit Margin: CEPS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CEPS is unprofitable, and losses have increased over the past 5 years at a rate of 26.7% per year.
Accelerating Growth: Unable to compare CEPS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CEPS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-12%).
Return on Equity
High ROE: CEPS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.